What have we learned about optimal induction therapy for lupus nephritis (III through V) from randomized, controlled trials?

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 3, 2008, Pages 895-898

  Clark, William F ^a   Sontrop, Jessica M ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ARTICLE; DRUG COMBINATION; EVIDENCE BASED MEDICINE; HOSPITALIZATION; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; METHODOLOGY; MORTALITY; PATHOLOGY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 44649127539     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00170108     Document Type: Article

References (11)

1. Illei GG, Austin HA III, Crane M, Collins L, Gourley MF, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Steinberg AD, Klippel JH, Balow JE, Boumpas DT: Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 135: 248-257, 2001
2. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiai GD, de Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gul A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns J-P, Cervera R: Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46: 2121-2131, 2002
3. Chan T-M, Tse K-C, Tang CS, Mok M-Y, Li F-K, for the Hong Kong Nephrology Study Group: Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 16: 1076-1084, 2005
4. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB: Mycophenolate mofetil or intravenous cyclophosphamide for lupus, nephritis. N Engl J Med 353: 2219-2228, 2005
5. Appel GB, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Solomons N, Wofsy D: Mycophenolate mofetil compared with intravenous cyclophosphamide as induction therapy for lupus nephritis: Aspreva Lupus Management Study (ALMS) results [Abstract]. J Am Soc Nephrol 18:47A; SA-FC057, 2007
6. Gourley MF, Austin HA III, Scott D, Yarboro CH, Vaughan EM, Muir J, Boumpas DT, Klippel JH, Balow JE, Steinberg AD: Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: A randomized, controlled trial. Ann Intern Med 125: 549-557, 1996
7. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gotzsche PC, Lang T, for the CONSORT Group: The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Ann Intern Med 134: 663-694, 2001
8. Ioannisdis JP, Patsopoulos NA, Evangelou E: Uncertainty in heterogeneity estimates in meta-analyses. BMJ 335: 914-916, 2007
9. Laupacis A, Straus S: Systematic reviews: Time to address clinical and policy relevance as well as methodological rigor. Ann Intern Med 147: 273-274, 2007
10. Korbet SM Schwartz MM, Evans J, Lewis EJ, for the Collaborative Study Group: Severe lupus nephritis: Racial differences in presentation and outcome. J Am Soc Nephrol 18: 244-254, 2007
11. Drazen JM, Morrissey S, Curfman GD: Open clinical trials. N Engl J Med 357: 1756-1757, 2005